Gossamer CCO gets 5.8M FDA-linked stock options
Gossamer Bio, Inc. (GOSS) reported that Chief Commercial Officer Robert Paul Smith Jr. received a stock option grant for 5,800,051 shares of common stock on August 24, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Gossamer Bio, Inc. (GOSS) reported that Chief Commercial Officer Robert Paul Smith Jr. received a stock option grant for 5,800,051 shares of common stock on August 24, 2026. The option has an exercise price of $0.175 per share and expires on August 23, 2036. According to the vesting terms, 50% of the shares vest upon FDA approval of seralutinib, and the remaining 50% vest in 24 equal monthly installments after that approval, subject to continuous service. If FDA approval has not occurred within two years of the grant date, vesting instead begins in 24 equal monthly installments starting two years after the grant date, also subject to continued service.
Insider Trade Summary
Grant/Award: 5,800,051 shares
Grant/Award
1 txn
Insider
Smith Robert Paul JR
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 5,800,051 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,800,051 contracts (Direct)
Footnotes (1)
- F1. 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Key Figures
Stock options granted: 5,800,051 shares
Exercise price: $0.175 per share
Options outstanding after grant: 5,800,051 options
+4 more
7 metrics
Stock options granted
5,800,051 shares
Number of option shares granted on August 24, 2026
Exercise price
$0.175 per share
Conversion or exercise price of the stock option
Options outstanding after grant
5,800,051 options
Total derivative securities beneficially owned following the transaction
Vesting upon FDA approval
50% of option shares
Portion that vests upon FDA approval of seralutinib, subject to service
Post-approval vesting schedule
1/24th monthly of remaining 50%
Monthly vesting of remaining shares after FDA approval, subject to service
Alternative vesting start
Two years after grant date
If FDA approval not obtained within two years of grant
Option expiration date
August 23, 2036
Expiration date of the stock option
Key Terms
Stock Option (Right to Buy), exercise price, FDA approval, continuous service, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "0.1750""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FDA approval medical
"will vest upon FDA approval of seralutinib"
FDA approval is the U.S. Food and Drug Administration’s formal authorization for a drug, vaccine, or medical device to be marketed and sold after reviewers determine it meets standards for safety and effectiveness. For investors it’s a pivotal milestone because it opens the door to legal, large-scale sales and can sharply boost revenue potential while reducing regulatory uncertainty—like receiving a safety certificate that lets a new bridge carry traffic and tolls.
continuous service regulatory
"subject to the Reporting Person's continuous service to the Issuer"
grant date financial
"two years following the grant date of the option"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity award did GOSS grant to its Chief Commercial Officer?
Gossamer Bio (GOSS) granted Chief Commercial Officer Robert Paul Smith Jr. a stock option covering 5,800,051 shares of common stock with an exercise price of $0.175 per share, expiring on August 23, 2036, as reported in this Form 4.
How do the stock options granted by GOSS to the CCO vest?
For the GOSS option grant, 50% of the shares vest upon FDA approval of seralutinib. The remaining 50% vest in 24 equal monthly installments after that approval, in each case conditioned on the executive’s continuous service on each vesting date.
What happens to the GOSS option vesting if FDA approval of seralutinib is delayed?
If FDA approval of seralutinib has not occurred by two years after the option grant date, then 1/24th of the total shares subject to the option vests monthly over 24 months starting two years after grant, subject to continuous service.
What is the exercise price and expiration date of the GOSS stock option grant?
The stock option granted by Gossamer Bio (GOSS) to its Chief Commercial Officer has an exercise price of $0.175 per share and an expiration date of August 23, 2036, as disclosed in the Form 4 derivative transaction details.
How many derivative securities does the GOSS executive hold after this Form 4 transaction?
Following the reported grant, the executive holds 5,800,051 stock options directly, corresponding to 5,800,051 underlying shares of Gossamer Bio common stock, as indicated by the total derivative securities beneficially owned after the transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
